Brokerages expect Retrophin, Inc. (NASDAQ:RTRX) to post $40.82 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Retrophin’s earnings. The highest sales estimate is $42.50 million and the lowest is $39.14 million. Retrophin reported sales of $33.95 million during the same quarter last year, which would suggest a positive year over year growth rate of 20.2%. The business is expected to announce its next quarterly earnings report on Thursday, November 2nd.
According to Zacks, analysts expect that Retrophin will report full-year sales of $40.82 million for the current financial year, with estimates ranging from $152.69 million to $154.80 million. For the next year, analysts expect that the company will post sales of $184.40 million per share, with estimates ranging from $184.19 million to $184.60 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that follow Retrophin.
Retrophin (NASDAQ:RTRX) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.10). Retrophin had a negative net margin of 48.74% and a negative return on equity of 7.31%. The business had revenue of $38.80 million for the quarter, compared to analyst estimates of $37.36 million. During the same period in the prior year, the business earned $0.07 EPS. The company’s revenue for the quarter was up 16.5% compared to the same quarter last year.
A number of research analysts have issued reports on RTRX shares. BidaskClub upgraded Retrophin from a “hold” rating to a “buy” rating in a research note on Wednesday, August 16th. ValuEngine upgraded Retrophin from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Two analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Retrophin has a consensus rating of “Buy” and an average target price of $32.33.
COPYRIGHT VIOLATION WARNING: This piece was reported by Markets Daily and is the property of of Markets Daily. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.themarketsdaily.com/2017/09/26/retrophin-inc-rtrx-expected-to-post-quarterly-sales-of-40-82-million.html.
In other Retrophin news, COO Neil F. Mcfarlane sold 1,378 shares of the company’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $22.50, for a total value of $31,005.00. Following the completion of the transaction, the chief operating officer now owns 13,622 shares in the company, valued at approximately $306,495. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.41% of the stock is owned by corporate insiders.
Large investors have recently made changes to their positions in the business. Weiss Multi Strategy Advisers LLC bought a new position in Retrophin in the 1st quarter valued at $185,000. Point72 Asset Management L.P. grew its stake in Retrophin by 133.8% in the 1st quarter. Point72 Asset Management L.P. now owns 964,800 shares of the biopharmaceutical company’s stock valued at $17,810,000 after purchasing an additional 552,065 shares during the period. Virginia Retirement Systems ET AL grew its stake in Retrophin by 99.2% in the 1st quarter. Virginia Retirement Systems ET AL now owns 75,100 shares of the biopharmaceutical company’s stock valued at $1,386,000 after purchasing an additional 37,400 shares during the period. FMR LLC grew its stake in Retrophin by 24.8% in the 1st quarter. FMR LLC now owns 1,958,875 shares of the biopharmaceutical company’s stock valued at $36,161,000 after purchasing an additional 389,714 shares during the period. Finally, Emory University bought a new position in Retrophin in the 2nd quarter valued at $1,767,000.
Shares of Retrophin (NASDAQ RTRX) traded up 0.48% during midday trading on Wednesday, reaching $23.15. The company’s stock had a trading volume of 346,694 shares. Retrophin has a one year low of $15.55 and a one year high of $25.11. The firm has a 50-day moving average of $22.97 and a 200-day moving average of $19.66. The stock’s market cap is $888.61 million.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.